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Background: Extensive encircling pulmonary vein isolation (EEPVI) is eﬀective for atrial
ﬁbrillation (AF). However, the deﬁnition of success following ablation is commonly based on
the lack of symptoms. The purpose of this study was to determine the incidence of recurrences
of AF by daily transtelephonic electrocardiogram (T-ECG), as compared with Holter ECG,
after ablation of AF.
Methods: Twenty-two patients with AF underwent EEPVI. Holter ECG tests were
performed at one, three, and six months, in addition to a daily T-ECG for the ﬁrst 180 days
after ablation.
Results: A total of 6012 T-ECGs were obtained. Of these, 18.9% (1136) showed AF.
Patients with AF were asymptomatic for 41.4% (470) of the episodes. Additionally, in 64%
(14 of 22) of the patients, AF recurrences were recorded by T-ECG, whereas Holter ECG tests
did not detect AF recurrences in 50% of the patients (7 of 14).
Conclusions: T-ECG is better than Holter ECG in detecting AF relapses. The absence of
symptoms should not be interpreted as absence of AF.
(J Arrhythmia 2009; 25: 130–134)
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Introduction
Radiofrequency catheter ablation has become an
eﬀective treatment for drug-refractory atrial ﬁbrilla-
tion (AF).1–3) The clinical eﬃcacy for ablation
procedures have been based in large part on patient
symptoms suggestive of AF, routine electrocardio-
grams (ECGs), or 24-h Holter recordings. Although
AF is often associated with typical symptoms such as
palpitations, dizziness, and dyspnea, a signiﬁcant
proportion of patients remain asymptomatic, espe-
cially in the setting of the anti-arrhythmic drug
administration,4–6) and the most important problem
associated with asymptomatic AF is the need for oral
anticoagulation after the ablation procedure. The
results of a review of studies comparing Holter
monitors and transtelephonic event monitors in the
diagnosis of palpitations found that the diagnostic
yield was 66 to 83 percent when transtelephonic
event monitors were used for monitoring, compared
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to 33 to 35 percent when Holter monitors were
used.7) We compared the diagnostic yield of trans-
telephonic event monitors with those of Holter
monitoring to determine whether transtelephonic
event monitoring is a reliable and objective means
to determine when to stop anticoagulation therapy in
patients after catheter ablation for AF.
Methods
Patient population
Twenty-two of 133 consecutive patients who
underwent catheter ablation for atrial ﬁbrillation
gave consent, and were thus enrolled in our study.
AF is classiﬁed as paroxysmal if episodes terminate
spontaneously in less than seven days, and persistent
if episodes continue beyond seven days. Long-
standing persistent AF was deﬁned as AF lasting
for more than 1 year. In our study, there were 9
patients with paroxysmal and 13 with persistent AF,
including 7 with long-standing AF.
Study protocol
All patients gave informed, written consent to be
enrolled in the study. A clinical examination, thyroid
function test, electrocardiogram, chest radiography,
transthoracic and transesophageal echocardiography,
and three-dimensional computed tomography to
reconstruct pulmonary vein (PV) and left atrium
(LA) were routinely performed. All patients were
treated with oral anticoagulants using warfarin
potassium to achieve an international normalized
ratio of 1.6 to 2.6 for more than two months before
catheter ablation.
Electrophysiological study
After informed written consent was obtained, an
electrophysiological study was performed in the
postabsorptive state under light sedation.8) All anti-
arrhythmic agents had been discontinued for >5
half-life periods. Oral anticoagulation was replaced
by drip infusion of heparin >72 hours before
ablation, and heparin ceased 3 hours before the
procedure. After internal jugular and femoral vein
punctures were performed, a heparin bolus (100
U/kg) was administered, and afterward, continuous
infusion of heparin was provided, maintaining an
activated clotting time value between 250 and 300
seconds. Surface ECG and bipolar endocardial
electrograms were continuously monitored and stor-
ed on a computer-based digital ampliﬁer/recorder
system for oﬄine analysis (Bard Electrophysiology).
Intracardiac electrograms were ﬁltered from 30 to
500Hz and measured at a sweep speed of 100mm/s.
Catheter ablation
The following catheters were introduced via the
right femoral vein and right internal jugular vein for
electrophysiological tests and ablation: (1) a 20-pole
catheter (Woven Diagnostic Electrode Catheter,
Bard Electrophysiology) was positioned in the
coronary sinus; (2) a circumferential 20-pole cath-
eter (Lasso, Biosense-Webster) was introduced
into the PV after transseptal access with the use of
a long sheath (Mullins 8F transseptal Catheter
Introducer Set, Medtronic, and Swartz SR0, St.
Jude Medical) and (3) a 4-mm tip ablation catheter
(Navistar, Biosense-Webster) was used for map-
ping and ablation. After LA reconstruction, each PV
ostium was identiﬁed by selective venography and
tagged on the electro-anatomical map. Radiofre-
quency energy was delivered with a target temper-
ature of 55 C and a maximal power limit of 30W.
The end point of the PV isolation was deﬁned by
complete elimination or dissociation of PV poten-
tials, as determined by the circumferential catheter.9)
LA roof ablation was performed in 10 patients by the
creation of a contiguous line of ablation lesions
joining the superior PVs.10)
Follow-up
Patients with paroxysmal AF received no anti-
arrhythmic drugs after ablation, and patients with
persistent AF received an anti-arrhythmic drug
within three months after ablation. At 1, 3, and 6
months after ablation, patients underwent clinical
review, and a Holter ECG was performed to identify
asymptomatic arrhythmias.
Transtelephonic ECG recorder
A transtelephonic ECG (T-ECG) is an ECG that is
recorded outside the hospital and then sent to the
hospital over the telephone. Patients were supplied
with a T-ECG recorder (EV-50, Clinical Supply Co.,
Kagamihara, Japan) and instructed on its use. Up to
three single-lead ECGs with a ﬁxed length of 30
seconds could be stored on the card. Patients were
asked to record at least two T-ECGs per day,
regardless of symptoms, and also at the onset of any
symptoms. T-ECG follow-up continued for 6 months
post ablation and was stored in a database. Patients’
comments on the T-ECGs were recorded and
submitted to the physicians at the outpatient clinic.
Comments were stratiﬁed into three categories:
asymptomatic, symptomatic, or not speciﬁed. Symp-
toms included palpitations (short lived), tachycardia
(long lasting), and chest discomfort. T-ECGs were
analyzed by two independent cardiologists and
diagnosed as sinus rhythm (SR), AF, atrial tachy-
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cardia (including atrial ﬂutter) of 30-second dura-
tion, and premature atrial or ventricular contraction.
Anticoagulation therapy
Patients were reloaded with warfarin on the day
after the ablation procedure, until their international
normalized ratio was therapeutic. Warfarin treatment
was stopped six months after ablation if AF was not
detected by both Holter ECG and T-ECG recorded
between 3 and 6 months after ablation, without the
use of anti-arrhythmic drugs.
Statistical analysis
All values are expressed as mean SD. Compar-
ison between groups was performed with a two-
tailed Student t test. Qualitative parameters were
compared by chi-square analysis or Fisher’s exact
test. Statistical signiﬁcance was established at
P < 0:05.
Results
Clinical characteristics (Table)
Among the 22 patients enrolled, 19 were male,
with a mean age of 64 14 years (range 21 to 74
years). Their arrhythmic history lasted a median of
seven years (range 1 to 35 years), and they had tried
anti-arrhythmic drugs for a mean of 3 1 (range 1 to
6). Baseline disease was present in 15 patients
(69%): hypertension in 14 patients, ischemic heart
disease in 3 patients, history of stroke in 5 patients,
and diabetes mellitus in 2 patients. The mean left
atrial diameter was 40 7mm (range 31 to 58mm),
and the mean left ventricular ejection fraction was
61 7% (range 46% to 72%).
Catheter ablation
All target veins were successfully isolated requir-
ing 75 10min (range 58 to 74min) of radiofre-
quency application. The mean procedure duration
was 213 29min (range 165 to 240min) and the
mean ﬂuoroscopic exposure was 32 5min (range
25 to 36min). No complications were observed in
any of the patients. A second session was not
performed in any of the patients with recurrence of
AF in this study.
Follow up
We obtained 66 Holter recordings (3 Holter
recordings per patient). By means of standard ECG
and Holter recording, 7 patients (31.8%) had an AF
recurrence documented, and all of the 22 patients
had at least more than one premature atrial contrac-
tion in their Holter recordings.
Transtelephonic ECG recordings
We obtained a total of 6012 T-ECG recordings
(mean 273 T-ECGs per patient). Due to low signal
quality, 418 (7.0%) recordings were excluded. Sinus
rhythm, AF, atrial tachycardia, and premature atrial
contraction (PAC) were diagnosed for 3817 (63.5%),
1136 (18.9%), 253 (4.2%), and 379 (6.3%) T-ECGs,
respectively. Of the 1136 T-ECGs recorded during
AF, 666 (59%) episodes were correctly recognized,
but 470 (41%) recordings were not associated with
symptoms. About half of the 379 T-ECGs with PAC
were recorded with symptoms and 83% of the 253
T-ECGs with AT were recorded without symptoms.
A total of 965 T-ECGs recorded simultaneously
with symptoms were: AF in 666 (69.0%), premature
atrial contraction in 205 (21.2%), sinus rhythm in 47
(4.9%), atrial tachycardia in 42 (4.4%), and prema-
ture ventricular contraction in 5 (0.5%). A total of
4629 T-ECGs recorded without symptoms revealed
sinus rhythm in 3770 (81.4%), AF in 470 (10.2%),
atrial tachycardia in 211 (4.6%), premature atrial
contraction in 174 (3.8%), and premature ventricular
contraction in 4 (0.1%) (Figure).
Comparison between T-ECG and Holter ECG for
the detection of arrhythmia after catheter ablation
During T-ECG recordings 14 (8 symptomatic and
6 asymptomatic) of the 22 patients (63.6%) had AF
recurrences, whereas Holter ECG could document
AF recurrences in only 7 of these 14 patients
(P < 0:05). In other words, T-ECG could document
AF in 7 patients (5 symptomatic and 2 asympto-
matic) in whom Holter recordings or routine ECGs
could not detect AF. Holter recording could detect
premature atrial contractions in all of the 22 patients,
Table Baseline clinical characteristics of the patients
n ¼ 22
Age (years) 64 14
Male, n (%) 19 (86)
Duration of AF (months) 84 100
Number of Antiarrhythmic drug 3.3  1.4
LA diameter (mm) 40 7
LV ejection fraction (%) 61 7
Paroxysmal AF/Persistent AF 9/13
Hypertension (%) 14 (64)
Ischemic Heart Disease (%) 3 (14)
Valvular Disease (%) 0 (0)
Cerebral infarction (%) 5 (23)
Diabetes Mellitus (%) 2 (9)
Continuous valuables are shown as mean SD.
AF: atrial ﬁbrillation, LA: left atrial, LV: left ventricular, n:
number
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while T-ECG detected premature atrial contractions
in 17 of 22 patients (P < 0:05).
Anticoagulation therapy
At 6 months after ablation, 11 of 22 patients
stopped taking warfarin, while the remaining con-
tinued. Nine patients took anti-arrhythmic drugs;
bepridil in four, cibenzoline in one, pilsicainide in
one, propafenone in one, beta-blockade in one,
bepridil and pilsicainide in one, and three of them
had symptomatic and one of them had asymptomatic
AF attacks. None of the 22 patients developed stroke
or systemic embolism for a mean of 23 months
during the follow up period.
Discussion
This study demonstrated that the detection rate for
AF after catheter ablation of AF was higher using T-
ECG compared with that of Holter ECG. Among 14
patients with AF recurrence, 41.4% were asympto-
matic according to their T-ECG recordings. Further-
more, 10.2% of a total of 4629 recorded T-ECGs
without symptoms were shown to exhibit AF.
Arya et al.11) reviewed various studies addressing
asymptomatic AF episodes. They concluded that the
high prevalence of asymptomatic AF together with
the poor correlation between symptoms and AF
should caution physicians against relying on symp-
toms to make clinical decisions. Although the best
device that can detect the recurrence of AF is an
implanted device such as a pacemaker12) or an
implantable loop recorder,13) it is diﬃcult to implant
these devices in every patient. Comparable results
are also recently reported during T-ECG3) and 7-day
Holter monitoring.14) In this study, we carefully
stopped the anticoagulation therapy when there was
an absence of AF monitored by the T-ECG and
Holter ECG. Thus, no patients developed stroke or
systemic embolism during the follow up period.
Clinical implications
The most important problem underlying asympto-
matic AF is the need for oral anticoagulation after
the ablation procedure. Therefore, withdrawal of
oral anticoagulation after ablation should be consid-
ered carefully, and be based not on patient symp-
toms, but on reliable and objective measures such
as a daily T-ECG combined with long-term Holter
records.
Study limitations
The study has two major limitations: 1) The T-
ECG lasted only 30 seconds, so some asymptomatic
AF episodes may not have been recorded. 2) No
comparisons among the T-ECGs with continuous
monitoring employing automatic AF detecting de-
vices were done to accurately estimate the number
965 T-ECGs with symptoms 4629 T-ECGs without symptoms(n)
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Figure
Number of transtelephonic electrocardiogram recordings showing atrial ﬁbrillation, premature atrial contraction, atrial tachycardia,
premature ventricular contraction, or sinus rhythm, with and without associated symptoms. Total numbers of recorded transtelephonic
electrocardiograms and the percentages are given on bottom of the diagram.
AF: atrial ﬁbrillation, AT: atrial tachycardia, n: number of recorded transtelephonic electrocardiogram, PAC: premature atrial contraction,
PVC: premature ventricular contraction, SR: sinus rhythm, T-ECGs: transtelephonic electrocardiograms
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of T-ECG recordings per day required during the
complete follow up. However, all patients recorded
T-ECGs twice a day, and we could observe a higher
incidence of persistent AF recurrences that lasted
more than 48 hours. This time is important because
the potential risk for forming LA thrombus is greater
when the AF lasts over 48 hours, even in asympto-
matic patients.
Conclusions
T-ECG is better than Holter ECG in evaluating
AF recurrence after catheter ablation. The absence of
symptoms should not be interpreted as absence of
AF. Anticoagulation therapy could be stopped after
successful ablation when using T-ECG to evaluate
the potential for AF recurrence.
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